Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Down 32.8% in March

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the target of a large decline in short interest in March. As of March 13th, there was short interest totaling 19,232 shares, a decline of 32.8% from the February 26th total of 28,626 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average trading volume of 34,499 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Trading of Redhill Biopharma

A hedge fund recently bought a new stake in Redhill Biopharma stock. Gagnon Securities LLC acquired a new stake in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 17,822 shares of the biotechnology company’s stock, valued at approximately $39,000. Gagnon Securities LLC owned about 0.54% of Redhill Biopharma at the end of the most recent quarter. Institutional investors own 7.20% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Redhill Biopharma in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Redhill Biopharma Stock Performance

Shares of Redhill Biopharma stock traded down $0.03 during trading on Friday, hitting $0.75. The company’s stock had a trading volume of 28,646 shares, compared to its average volume of 24,894. Redhill Biopharma has a 52 week low of $0.75 and a 52 week high of $3.31. The company has a market capitalization of $3.83 million, a PE ratio of 0.00 and a beta of 4.91. The company has a fifty day simple moving average of $1.02 and a two-hundred day simple moving average of $1.26.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.